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Available online 4 March 2008Estrogen receptors (ER) are present in connective tissues and therefore it is possible that the loss of estrogen
after menopause inﬂuences the integrity of these tissues, contributing to development of degenerative
conditions such as osteoporosis and osteoarthritis in a subset of women. Aberrant expression of matrix
metalloproteinases (e.g. MMP-1 and MMP-13) has been implicated in the progression of these diseases. The
present study investigated potential molecular mechanisms involved in the regulation of expression of MMP-
1 and MMP-13 promoter variants by ER-α and ER-β (+/−estrogen) in a transient transfection system. The
results demonstrate that the activity of human MMP-1 and MMP-13 polymorphic variants is elevated in the
presence of ER-α and ER-β, and the single nucleotide polymorphisms present in the promoters of MMP-1 and
MMP-13 variants leads to differential activities in response to the ER isoforms. Furthermore, the inﬂuence of
17-β estradiol also varies depending upon whether the alpha or the beta isoform of ER is the modulator of
these polymorphic variants. These ﬁndings support the conclusion that ER isoforms may be contributing to
disease development and/or progression in genetically distinct subsets of women following menopause, and
provide mechanistic insights into how such contributions are manifested.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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The incidence of osteoarthritis (OA) and osteoporosis (OP) is more
prevalent in females than in males, particularly after menopause
when estrogen levels in the body decline. Degradation of articular
cartilage is a feature of OA and degradation of bone matrix a feature of
OP. In both conditions aberrant expression of matrix metalloprotei-
nases (MMPs) has been implicated (reviewed in [1–3]). In addition,
depletion of estrogen as a result of ovariectomy has been observed to
lead to increased cartilage degradation in a rodent model [4,5]. Fur-
thermore, in vivo animal studies on ovariectomized sheep [6] and
monkeys [7] also suggest that estrogen replacement therapymay have
a protective effect against OA as it reverses the damage to biome-
chanical properties of cartilage and/or decreases the severity of
cartilage degradation. In vitro studies, which have investigated the
effects of 17-β estradiol on IL-1 beta inducedMMP expression, suggest
that high concentration of estrogen can lead to increased IL-1 beta
stimulated cartilage degradation [8]. Destruction of cartilage has also
been associated to production of catabolic factors such as NO by
chondrocytes [9]. It is well known that the major actions of theand Arthritis Research, Faculty
N.W., Calgary, Alberta, Canada
l rights reserved.hormone estrogen are generally mediated through two intracellular
receptors, ER-α and ER-β (discussed in [10,11]).
Previous studies have shown that both ER-α and ER-β can elevate
the activity of the promoter for the rabbit MMP-13, a member of the
family of MMPs. Furthermore, those in vitro studies have also shown
that in the presence of the estrogenic ligand 17-β estradiol, the
enhancement of rabbit MMP-13 promoter activity by ER is depressed
[10,11]. Thus, it would appear that the receptors for estrogen have
potential to exhibit a modulatory role onMMP-13 expression, and it is
governed in part by the presence and absence of the hormone
estrogen.
Studies in the progression of atherosclerosis lesions in the
abdominal aorta led to the discovery of two polymorphic variants in
the promoter of theMMP-13 gene [12]. Sequence analysis of theMMP-
13 promoter revealed an insertion of an adenine residue at position
−291 leading to a stretch of 12A residues in one variant form. Alter-
nately, in the other MMP-13 allele there is an absence of the adenine
residue at nt −291 leading to a stretch of only 11 adenine residues.
Furthermore, an A to G transition at nt −77 changes the PEA-3
transcriptional regulatory site from AGGAAG to GGGAAG, thus leading
to the formation of another polymorphic mutation. Increased
development of atherosclerosis lesions in the young black males has
been attributed, in part, to the polymorphisms observed in the MMP-
13 promoter [12]. Thus far, it is not known whether these MMP-13
polymorphic promoter variants are inﬂuenced differently by the alpha
and beta isoforms of ER in vitro.
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the metalloproteinase family have also been detected. In particular,
the 1G and 2 G variants are two well characterized polymorphic
variations in the promoter for MMP-1 [14]. The insertion of a guanine
residue at position −1607 leads to the formation of an Ets transcription
factor binding site which along with the AP-1 site at nt −1602 leads to
increased transcription of the 2G variant [13,14]. In contrast, the 1G
variant lacks this insertion of a guanine residue in its promoter and
consequently is reported to exhibit lower basal transcriptional levels
[13,14]. It is reported that MMP-1 is a proteinase produced bymultipleFig.1. Effect of increasing ER-α or ER-β on the activity ofMMP-1 promoter variants. A. Rabbit s
constructs (1G or 2G), ER-β (pSG5-ERβ), and the internal control plasmid, pRL-SV40. Increasi
Cells transfected with 1G or 2G alone were used as controls. Luciferase activity was expresse
Values represent the mean+/−S.E. for three determinations.♣ pb0.001 as compared with 1G
of ER-β. φ pb0.001 comparing the activity of 1G and 2G in the absence of exogenously ad
exogenously added ER-β. B. Rabbit synoviocytes (HIG-82) were transiently co-transfected wit
control plasmid, pRL-SV40. Increasing concentrations of pSG5-ERα ranging from (0.5 to 2
controls. Luciferase activity was expressed as the ratio of 1G ﬁreﬂy luciferase activity an
determinations. ‡ pb0.05 as compared with 2G activity in the absence of ER-α.● pN0.05 not
with 1G activity in the absence of ER-α.φ pb0.001 comparing the activity of 1G and 2G in the abs
thepresenceof exogenouslyaddedER-α. C.Rabbit synoviocytes (HIG-82)were either left un-tran
protein extracts from transfected andun-transfected cellswere separated on a 10% SDS-PAGE gel
using the Mouse monoclonal to ER-β (ab1103) (obtained from AbCam. Inc.) and rabbit polyclona
HIG-82 cells (Control); Lane 2. HIG-82 cells transfected with pSG5-ERβ. Lane 3. HIG-82 cecells in the joint inclusive of synovial cells, and it is believed to
inﬂuence the onset and progression of osteoarthritis by promoting
degradation of collagen ﬁbrils [2]. Besides arthritis, MMPs are also
postulated to play a role in the metastasis of the tumors. Previous
studies have indicated that the hormone estrogen has an inhibitory
effect on the activities ofMMPs in breast cancer cells [15]. Interestingly,
ovariectomy in rats leads to amarked elevation in the expression of the
rodent form of MMP-13 in bone [16].
Joint tissues are recognized as estrogen responsive tissues as several
studies have identiﬁed estrogen receptors in several connective tissuesynoviocytes (HIG-82) were transiently co-transfectedwith the humanMMP-1 promoter
ng concentrations of pSG5-ERβ ranging from (0.5 to 2 μg) were used in this experiment.
d as the ratio of 1G ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity.
activity in the absence of ER-β. ‡ pb0.0001 as compared with 2G activity in the absence
ded ER-β. pb0.001 comparing the activity of 1G and 2G in the presence of
h the humanMMP-1 promoter constructs (1G or 2G), ER-α (pSG5-ERα), and the internal
μg) were used in this experiment. Cells transfected with 1G or 2G alone were used as
d the Renilla luciferase reporter activity. Values represent the mean+/−S.E. for three
signiﬁcant as compared with 2G activity in the absence of ER-α.♣ pb0.005 as compared
ence of exogenously added ER-α. pb0.005 comparing the activity of 1G and2G in
sfectedorwere transiently transfectedwith either ER-α (pSG5-ERα) or ER-β (pSG5-ERβ). The
and then transferred onto a nitrocellulosemembrane.Western blot analysiswas conducted
l antibody for ER-α: ER-α(HC-20) (Santa Cruz Inc.). Lane 1 represents the un-transfected
lls transfected with pSG5-ERα.
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furthermore these isoforms are inﬂuenced differently by estrogen
agonists and antagonists. Therefore, the aim of the present study was to
understand the inﬂuence of ER-α and ER-β on several of the known
polymorphic variants of the human MMP-13 and MMP-1 promoters,
and to decipher the potential role of estrogen in such modulation.
Polymorphisms found in the MMP promoters and their response to the
changes in hormonal levels may provide a partial explanation for why
only subsets of women develop osteoarthritis or osteoporosis with
different clinical phenotypes following menopause.
2. Materials and methods
2.1. Cell culture
The rabbit synoviocyte cell line HIG-82 was obtained from the American Type
Culture Collection (Rockville, Md). Cells were maintained at 37 °C under 5% CO2 in
Ham's F-12 Nutrient Media (Life technologies) supplemented with 10% fetal calf serum
(Invitrogen Canada Inc.) and 1% penicillin/streptomycin. Cells were sub-cultured 1:4
after trypsinization with 0.25% trypsin. This cell line lacks endogenous ER and has been
used in previous studies [10,11].
2.2. Isolation and cloning of the human MMP-13 promoters
The MMP-13 promoter construct (12AA) was isolated from the total DNA obtained
from human HL-60 cells by ampliﬁcationwith PCR using speciﬁc primers generated from
published sequences [19]. This was labeled as the primary PCR reaction. The sequences of
the primers for the human MMP-13 gene used in this primary PCR reaction were:
Forward 5′-CTTCTGCAGGGGACCAAAGATG-3′ (nt −1174 to −1153).
Reverse 5′-CTCAAGAAGAGGAAGGCAGCCA-3′ (nt 60 to 39).Fig. 2. Inﬂuence of ligand, 17-β estradiol on the modulating effects of ER-α and ER-β on
transiently co-transfected with the human MMP-1 promoter constructs (1G or 2G), ER-α (p
transfected cells was treated with 10−8 M 17-β estradiol. Cells transfected with 1G or 2G alon
the ratio of 1G or 2G ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity. Value
activity of 1G+ER−α compared to the activity of 1G+ER-α (10−8 M estradiol). pb0.0
when compared to the activity of 1G and 2G without ER receptors or ligands.The secondary or nested PCR reaction used 1 μl of the primary PCR reaction as a
template. The sequences of the secondary primers were:
Forward 5′-CTGAGAATGGAAAGGGTGGAGGTC-3′ (nt −939 to −916).
Reverse 5′-TCTTGAATGGTGATGCCTGGG-3′ (nt 23 to 3).
The 939 bp PCR fragment obtained from the secondary reaction was cloned
directly into the PCR 2.1-TOPO vector (Invitrogen Inc.). Following this, the 939 bp
fragment was released from the PCR 2.1-TOPO vector by digestionwith KpnI/XhoI, and
subcloned into the KpnI/XhoI site of the promoterless pGL2 Basic Luciferase reporter
vector. The resulting plasmids were transformed into One shot E. coli and puriﬁed on
the QI-A spinMiniprep Kit (Qiagen, Mississauga, ON), according to the manufacturer's
instructions and subjected to sequencing analysis to verify the orientation and
accuracy of each construct. Two polymorphic MMP-13 constructs were identiﬁed, one
which had a stretch of 12 adenine residues and one with a stretch of 11 adenine
residues. The PEA-3 site beganwith an adenine residue— AGGAAG in these constructs
and hence they were given the label of 12AA and 11AA. Two more polymorphic
constructs 12AG and 11AG were generated with a guanine residue at the PEA—3 site
(GGGAAG) replacing the adenine residue. This was done using the Quick Change Site-
Directed Mutagenesis kit (Stratagene Inc).
2.3. Human MMP-1 promoter constructs
The human 1G and 2G MMP-1 promoter constructs were a generous gift from
Dr. C.E Brinckerhoff (Dartmouth Medical School, NH, USA). Both the 1G and 2G
constructs were subcloned into the pGL-3 luciferase expression vector. The deletion
fragments −1458 bp, −572 bp, −143 bp and −73 bp were generated by RT-PCR
using a 5′ forward primer containing the MMP-1 sequence along with a MluI site
(ACGCGT).
−1458 5′-CGACGCGTCCATAAGGTGCTGAAGTG-3′ (nt −1458 to −1441)
−572 5′-CGACGCGTATGGCCTGGCTCTGAGTAA-3′ (nt −572 to −555)
−143 5′-CGACGCGTCTGCTAGGAGTCACCAT-3′ (nt −143 to −126)
−72 5′-CGACGCGTTGAGTCAGACACCTCTGG-3′ (nt −72 to −55)MMP-1 promoter polymorphic variants. A and B. Rabbit synoviocytes (HIG-82) were
SG5ER-α) or ER-β (pSG5-ERβ), and the internal control plasmid, pRL-SV40. One set of
e were used as controls in Fig. 2A or 2B respectively. Luciferase activity was expressed as
s represent themean+/−S.E. for three determinations. pN0.05 not signiﬁcant:
5: activity of 1G+ER-β compared to the activity of 1G+ER-β (10−8 M estradiol). ‡ pb0.05:
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RT-PCRs.
5′-CCAAGCTTCAGTGCAAGGTAAGTG-3′ (nt −51 to −36)
The PCR products were puriﬁed and digested with MluI/HindIII. The ﬁnal products
were then ligated into MluI/HindIII digested pGL3 basic Vector.
The PEA-3 site consensus sequence AGGAAG at nt −1385 was altered to AGCGAG
using the Quick Change Site-Directed Mutagenetic kit (Stratagene, La Jolla, CA USA) and
the nt −1458 construct. The mutation was veriﬁed by sequencing. The orientation and
integrity of all reporter constructs were assessed by DNA sequencing.
2.4. Additional control and expression plasmids
The internal control plasmid for the dual luciferase assays, pRLSV40, which
constitutively expresses the Renilla form of luciferase under the strong SV40 promoter,
was obtained from Promega (Madison, WI). The expression vectors for ER-α (pKCR2-
ERα) and ER-β (pKCRE-ER-β) were a generous gift fromDr. Pierre Chambon (Strasbourg,
France) and Dr. Koen Dechering (Organon, The Netherlands), respectively. Since the ER-Fig. 3. A) Schematic representation of the cloned DNA constructs containing promoter elemen
lack the distal Ets transcription factor binding site and the AP-1 binding sites present at di
promoter region stretching from transcriptional regulatory site, TATA box, at nt −30 to the
construct 143 lacks this PEA-3 plus three other AP-1 sites. The p73MMP-1 promoter fragment
were cloned into the vector, pGL2-Basic, which contains the promoterless luciferase gene. B)
ER-α. Rabbit synoviocytes, HIG-82 cells, were transiently co-transfected with 1G or deletion c
0.5 μg of ER-α (pSG5-ERα) and 0.05 μg of pRL-SV40. Luciferase activity was expressed as t
represent themean+/−S.E. for three determinations and are expressed as percentage of 1G lu
of 1G in the presence of ER-α. pb0. 0005 when compared to luciferase activity of
human MMP-1 in response to ER-β. HIG-82 cells were transiently co-transfected with 0.5
constructs of human MMP-1 promoter such as (−1458, −572 bp, −143 bp and −73 bp) and t
ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity. Values represent the m
activity in the presence of ER-β. ♣ pN0.05 not signiﬁcant. pb0. 005 when compared to lu
luciferase activity of 1G in the absence of ER-β. D) Inﬂuence of PEA-3 site at nt −1385 position
cells, were transiently co-transfected with 1G or mutated construct of human MMP-1 promo
0.05 μg of pRL-SV40. Luciferase activity was expressed as the ratio of ﬁreﬂy luciferase activit
determinations and are expressed as percentage of 1G luciferase activity in the presence of ER
of ER-α or ER-β.α and ER-β constructs were obtained in different vectors, the inserts were cleaved from
their original vectors and subcloned into the pSG5 vector. The orientation and integrity
of the inserts were conﬁrmed by sequencing.
2.5. Transient transfection and luciferase assay
The rabbit synoviocyte cell line, HIG-82, was transfected using the FuGene6
Transfection reagent (RocheMolecular, Indianapolis. IN) as directed by themanufacturer
and as described previously [20,10]. Previous analysis has revealed that this cell line is
devoid of detectable ERs [10,11]. Brieﬂy, HIG-82 cells were seeded on 12-well plates on
the day before transfection at a density of 1×105 cells/well. The cells were washed with
PBS prior to transfection and then transfected with a constant amount (1 μg) of reporter
plasmids (shown to be optimal inpreliminary studies; data not shown), pRLSV40 (50 ng)
and pSG5 vector alone (0.1–2 μg), pSG5-ERβ (0.5 μg–4 μg) or pSG5-ERα (0.5 μg) bymeans
of the Fugene 6 Transfection Reagent. Transfection was performed in Ham's F-12
NutrientMedium in the absence of serum. Immediately, after transfection,17-β estradiol
(E2) (Sigma, Oakville, ON) was added to the medium in appropriate wells of speciﬁc
experiments. Twenty four hours after transfection and (+/−) ligand treatment, thets of humanMMP-1. All the constructs −1458, −572, −143 and −73 bps used in this study
stal locations at −1607 and −1602 bps. The −1458 bp construct contains the proximal
PEA-3 site at nt −1385. The construct −572 lacks the PEA-3 at position nt 1385 and the
contains only the AP-1 promoter element and the TATA box. All the promoter fragments
Functional characterization of the promoter elements of human MMP-1 in response to
onstructs of humanMMP-1 promoter (−1458, −572 bp, −143 bp and −73 bp), along with
he ratio of ﬁreﬂy luciferase activity and the Renilla luciferase reporter activity. Values
ciferase activity in the presence of ER-α. ‡ pb0. 005when compared to luciferase activity
1G in the absence of ER-α. C) Functional characterization of the promoter elements of
μg pSG5-ERβ along with either the human MMP-1 DNA (1G construct) or deletion
he internal control plasmid, pRL-SV40. Luciferase activity was expressed as the ratio of
ean+/−S.E. for three determinations and are expressed as percentage of 1G luciferase
ciferase activity of 1G in the presence of ER-β. pb0. 0005 when compared to
of 1G promoter on its activity in response to ER-α and ER-β. Rabbit synoviocytes, HIG-82
ter (−p1458 M), along with 0.5 μg of ER-α (pSG5-ERα) or 0.5 μg of ER-β (pSG5-ERβ) and
y and the Renilla luciferase reporter activity. Values represent the mean+/−S.E. for three
-α or ER-β. pb0. 05 when compared to luciferase activity of 1G in the presence
Fig. 3 (continued ).
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buffered saline (PBS). The cells were then lysed directly in thewellswith 1× Passive Lysis
Buffer (Promega Corp.). Luciferase activitywas determined on cell lysates using a Turner
TD-20 illuminometer and the Dual Luciferase™ Reporter Assay kit (Promega Madison,
WI). All transfection experiments were performed in triplicate and repeated three or
more times with results very similar to those reported obtained.
2.6. Western blot analysis
The HIG-82 cells were either left un-transfected (Control) or were transiently
transfected with ER-α (pSG5-ER-α) or ER-β (pSG5-ER-β) for 24 h. At that time, the cells
were washed and then lysed in Mammalian Cell Lysis Kit buffer (Sigma Chemical Co).
The cellular extracts from control and transfected cells were separated on a 10% SDS-
PAGE gel and then transferred to a nitrocellulose membrane. Western blotting was
performed using a mouse monoclonal to ER-β (ab1103) (obtained from AbCam Inc.) or a
rabbit polyclonal antibody for ER-α: ER-α (HC-20) (Santa Cruz Inc.).
2.7. Statistical analysis
Statistical analysis of the data was performed using ANOVA, STDEVA, and STEYX in
the Excel 5.0 software.
3. Results
3.1. Inﬂuence of increasing concentrations of ER-β and ER-α on MMP-1
promoter variant activity
The effect of increasing concentrations of ER-β and ER-α on MMP-1
promoter activitywas examined inHIG-82 cells. Twowell characterized
MMP-1 promoter variants 1G and 2G were used in this study. HIG-82
cells were transiently co-transfected with increasing concentrations
(0.5, 1 and 2 μg) of pSG5-ER-β or pSG5-ER-α DNA, simultaneously witheither 1G or 2G constructs (1.0 μg) and the internal control plasmid,
pRL-SV40 (0.05 μg). After 24 h, the luciferase activity of the cell lysates
was determined. In the absence of exogenous ER-α or ER-β, 1G and 2G
activity were both detectable in the HIG-82 cells. Furthermore, the 2G
variant consistently exhibited an ∼2.5 fold higher activity than the 1G
variant. The results presented in Fig.1A suggest that co-transfectionwith
0.5 μg of ER-β had a signiﬁcant impact on activity levels of both the 1G
and 2GMMP-1 promoter constructs. The activity of the 1G variant in the
presence of ER-βwas elevated approximately∼4 foldwith respect to 1G
activity in the absence of ER-β. The activity of the 2G variant in the
presence of 0.5 μg of ER-β was elevated approximately ∼3.7 fold when
compared to the 2G activity in the absence of exogenously added ER-β.
The activity of the 1G construct increased ∼7.6 fold and ∼13 fold when
compared to 1G activity (−ER-β) in the presence of 1 and 2 μg of ER-β
respectively. Similarly, the 2G variant also exhibited a∼4.6 fold and∼7.3
increase in activity in the presence of 1 and 2 μg of ER-β respectively.
Although theactivityof the2Gvariantwasalwayshigher than thatof the
1G variant in the absence or presence of ER-β, the proportional increase
in activity for 2Gwas consistently less than the increase in activity for 1G
at different concentrations of ER-β. In addition, the ratio of activity of 2G
vs. 1G also decreased with increasing concentrations of ER-β.
The results presented in Fig. 1B, show evidence of the effect of the
alpha isoform of ER on the MMP-1 polymorphic constructs. The
activity of the 1G variant increased 2.2 fold, 2.6 fold and 3.6 fold with
concentrations of 0.5,1.0 and 2 μg of pSG5-ER-αDNA, respectively. The
activity of the 2G variant showed amodest∼1.2 fold increase at 0.5 and
1 μg of ER-α DNA and detected activity increased approximately 2-fold
with 2 μg of ER-β DNAwhen compared to 2G activity in the absence of
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compared to the 1G variant in the absence or presence of the ER-α
construct. These results indicate a strong inﬂuence of ER-α and ER-β on
the activity of MMP-1 promoter variants in this in vitro model system.
Western blot analysis conducted on transfected and un-trans-
fected cells indicated that un-transfected HIG-82 cells did not exhibit
the presence of either ER-α or ER-β proteins (Fig. 1C, Lane 1), and
furthermore the cells transfected with pSG5-ERβ or pSG5-ERα for
24 h exhibited the presence of these proteins at nearly identical
levels (Fig. 1C, Lanes 2 and 3). These results support the conclusion
that the differences in activity levels detected above were not due to
differences in the translation of the ER constructs.
3.2. Inﬂuence of 17-β estradiol on the modulating effects of ER isoforms
on the activity of MMP-1 promoter variants
Next, the effect of the estrogenic ligand, 17-β estradiol was
investigated on the ER-α and ER-β mediated augmentation of 1G andFig. 4. Comparison of the inﬂuence of ER-α and ER-β on the activity of polymorphic variant
present in the promoter of human MMP-13 DNA. The construct 11AA has a stretch of 11 ade
polymorphic variant 11AG has the same stretch of 11 adenine bases but the PEA-3 site starts
12 adenine residues but differ in the presence of adenine or guanine residues at the PEA-3 sit
of rabbit MMP-13 promoter region such as Runx domain (RD), p53, PEA-3 and AP-1 binding s
the promoterless luciferase gene. B. HIG-82 cells were transiently co-transfected with 0.5 μg
12AA and 12AG), promoter (1 μg) and the internal control plasmid, pRL-SV40 (0.05 μg). Lu
luciferase reporter activity and values represent the mean+/−S.E. for three determinations. T
the human MMP-13 constructs (+/−ER-α or ER-β) was expressed as percentage of the activ2G variant activities (see Fig. 2A). HIG-82 cells were co-transfected
with 1 μg of pSG5-ER-α or pSG5-ER-β and the 1G variant along with
0.05 μg of pRL-SV40DNA. The activity of the 1G variantwas found to be
elevated approximately 2-fold in the presence of ER-α and ∼3 fold in
the presence of ER-β. When 10−8 M 17-β estradiol was added to the
transfectionmedium, the elevation in 1G activity levels induced by ER-
β was found to decrease by approximately 75%. Interestingly, the
elevation in activity with the 1G variant in the presence of ER-α
remained uninhibited (pN0.05, NS) in the presence of same concen-
tration of 17-β estradiol (Fig. 2A, lane 3). When the ligand, 17-β
estradiol, was used at a concentration of 10–12 Mwith ER-α or ER-β, no
notable decreases in the activity of the 1G variant were again observed
(data not shown). Fig. 2B shows the response of the 2G construct with
ER-α or ER-β (−/+) 17-β estradiol. The activity of the 2G variant was
elevated modestly in the presence of ER-α and no decreases in activity
levels were again observed in the presence of 10−12 M 17-β estradiol
(data not shown). However, the activity of the 2G variant decreased by
∼30% when saturating amounts of 17-β estradiol (10−8 M) were useds of the MMP-13 promoter. A. Schematic representation of the polymorphic variations
nine residues. The PEA-3 site (AGGAAG) in this construct starts with an A residue. The
with a guanine residue (GGGAAG). Both the constructs 12AA and 12AG have a stretch of
e as indicated in the ﬁgure above. All four constructs contain all the known key elements
ites. All the promoter fragments were cloned into the vector, pGL2-Basic, which contains
of pSG5-ERβ or pSG5-ERα along with the human MMP-13 DNA constructs (11AA, 11AG,
ciferase activity was expressed as the ratio of ﬁreﬂy luciferase activity and the Renilla
he activity of 11AA transfected with pSG5ER-αwas set at 100%. The activity of the rest of
ity of 11AA (+ER-α). ♣ pN0.05 not signiﬁcant.
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approximately 3-fold when ER-β alone was present, and this elevation
was decreased ∼70% in the presence of 10−8 M 17-β estradiol. At a
concentration of 10–12 M, the ligand once again did not exert any
detectable impact on the activity of the 2G construct. These ﬁndings
support the concept that effects of estrogen modulation on the ER
isoforms may be different, and additionally these also inﬂuence the
polymorphic variants differently.
3.3. Functional characterization of the promoter elements of the MMP-1
promoter involved in mediating the inﬂuences of ER-α and ER-β (+/−)
ligands
In order to characterize the promoter elements of the human
MMP-1 promoter for their potential role in mediating the effects of
the ER isoforms, a series of 5′ deletion constructs, ranging in length
from 1458 bp to 73 bp of the MMP-1 promoter was generated (Fig. 3
panel A). The 1458 bp MMP-1 construct lacks the important Ets and
AP-1 binding sites present at position −1607 and −1602, respectively.
Previous studies have shown these sites to be of importance in the
activity of MMP-1 promoter (13). However, this construct still hasFig. 5. Polymorphisms in the MMP-13 promoter inﬂuence the response of the variants to th
transfectedwith either the polymorphic variants of the humanMMP-13 promoter (12AA,12A
were treated with 10−8 M17-β estradiol, for a period of 24 h post transfection. Luciferase a
reporter activity. Values represent the mean+/−S.E. for three determinations and are expresseveral other transcriptional regulatory sites present such as the
TATA box at −30 bp and AP-1 sites at nt −70, −181, −429 and −556,
and the PEA-3 sites at nt −88 and −1385. which are proximal to the
transcriptional start site. These constructs were used in co-transfec-
tion studies in HIG-82 cells along with ER-α or ER-β and the pRL-
SV40, followed by luciferase assays to determine activity. The results
presented in Fig. 3B demonstrate that the activity of the −1458
construct was 75% lower than that of the intact 1G promoter in the
presence of ER-α. In the presence of ER-β, a mean 70% decrease was
observed in the activity of the −1458 construct when compared to the
intact 1G construct (see Fig. 3C). Interestingly, the mean percent
decreases in activity observed for the −1458 construct with ER-α and
ER-β were not signiﬁcantly different. These results suggest that the
AP-1 site present at position −1602 plays a primary role in elevating
the activity of the MMP-1 promoter in response to ER-α and ER-β.
Additionally, the ETS binding site present at −1607 bp in the 2G
construct likely also contributes to the elevation in activity observed
with the ER isoforms.
Next, the 572 bp fragment of the MMP-1 promoter was examined
for activity +/−ER-α or ER-β. In contrast to the signiﬁcant decreases in
activity seen for the 1458 bp fragmentwith ER-α and ER-β, this shortere modulatory effects of ER isoforms. Rabbit synoviocytes, HIG-82, were transiently co-
G,11AA and 11AG alongwith 0.5 μg of ER-α (Fig. 5A) or ER-β (Fig. 5B) and pRL-SV40. Cells
ctivity was expressed as the ratio of ﬁreﬂy luciferase activity and the Renilla luciferase
sed as percentage of 11AA luciferase activity without treatment with any ligand.
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ER-α and a 49% increase in activity in the presence of ER-β (Fig. 3B and
C Bar 4). When compared to the promoter of the −1458 bp fragment,
this −572 bp fragment is missing the PEA-3 site at −1385 position.
These results imply that the promoter activity is regulated positively
and negatively by the various transcriptional regulatory sites of MMP-
1 in this cell line, and suggest a negative regulatory role for the PEA-3
site at the −1385 location. To conﬁrm this suggestion, the PEA-3 site at
−1385 in the −1458 construct was mutated to yield a construct
−1458M with this PEA-3 site inactivated. As shown in Fig. 3D, in the
presence of ER-α the activity of the mutated −1458 construct was
actually signiﬁcantly elevated compared to intact 1G. In contrast, in
the presence of ER-β, the activity was partially restored compared to
that with the 1G construct but the activity with the mutant was still
less than that with the 1G variant.
Furthermore, a MMP-1 promoter fragment which is only −143 bp
in length, was also assessed. A ∼68% increase in the promoter activity
as compared to intact 1G promoter activity was observed with this
construct when ER-α was the modulator. Alternately, when ER-β was
themodulator, the activity of this −143 bpMMP-1 construct decreased
moderately (∼5%) with respect to the intact 1G promoter construct.
While overall both ER isoforms elevated the activity of MMP-1
promoter, subtle differences in the response of these transcriptional
regulatory sites of the MMP-1 promoter to these ER isoforms were
detected. These observations are further corroborated by the response
of the −73 bp fragment of theMMP-1 promoter to the ER isoforms. The
−70 bp construct containing only the AP-1 site was tested along with
ER-α and a mean 24% decrease in the activity was observed compared
to the intact 1G variant. When ER-β was the modulator, the −73 bp
construct exhibited a mean 68% decrease in activity when compared
to the 1G promoter (Fig. 3B and C, Bar 5).
3.4. Comparison of the effects of ER-α and ER-β on the human MMP-13
polymorphic promoter variants
In this study, polymorphic promoter variants of a second matrix
metalloproteinase, MMP-13, were also analyzed. Fig. 4A illustrates the
fourpolymorphic constructs of thehumanMMP-13promoterused in this
study. The variant 12AA contains a stretch of 12A residues and the PEA-3
site has the consensus sequence AGGAAG. The 12AG variant contains a
stretch of 12A residues, but the PEA-3 site begins with a G residue. The
11AA and 11AG constructs contain the stretch of 11A residues and the
PEA-3 site has either an A or a G residue, respectively. The HIG-82 cells
were co-transfected with the individual human MMP-13 promoter
variants, along with ER-α or ER-β and the internal control plasmid, pRL-
SV40. After 24 h, luciferase assays were used to analyze the cell lysates.
As shown in Fig. 4B, no activity was observed for all four human
MMP-13 constructs in the absence of either ER-α or ER-β. Both pSG5-
ERα and pSG5-ERβ induced expression of the human MMP-13
polymorphic variants. Interestingly, the induction of 11AA and 11AG
MMP-13 promoter activity by the ER-β construct was consistently
approximately 4.7 times higher than that observed for an equivalent
amount of the ER-α construct (Fig. 4B). The polymorphic variants
12AA and 12AG showed an elevation of approximately ∼7.5 fold in
activity in the presence of ER-βwhen compared to the inﬂuence of ER-
α on these constructs. Furthermore, the activity of 12AA was 1.6 fold
higher than that of 11AA suggesting that the presence of an extra
adenine residue exerted a positive inﬂuence in elevating the activity of
the 12AA construct. Similarly, a 1.6 fold elevation in activity was
observed when comparisons were made between the 11AG and 12AG
constructs (Fig. 4B). These results suggest that ER-β is a stronger
modulator than ER-α of the human MMP-13 DNA constructs. The
number (11 or 12) of adenine residues also appear to have an impact
on the response of these constructs to ER-β with constructs with 12
adenine residues showing higher activity levels. Interestingly, this
impact was observed only with ER-β and not with ER-α.3.5. Polymorphisms in the human MMP-13 promoter lead to differential
responses to ER isoforms (+/−17-β estradiol)
In this aspect of the studies, polymorphic variants of the MMP-13
promoter were also analyzed for their response to the alpha and beta
isoforms of ER in the presence and absence of the estrogenic ligand 17-
β estradiol. The HIG-82 cells were co-transfected with the human
MMP-13 polymorphic variants along with ER-α or ER-β and the
internal control plasmid, pRL-SV40 in the presence and absence of 17-
β estradiol. After 24 h, luciferase assays were used to analyze the cell
lysates.
The results presented in Fig. 5A show the inﬂuence of ER-α on the
human MMP-13 constructs. The activity exhibited by the 11AA MMP-
13 promoter was used as the positive control and values obtained in
the presence of ER-αwere set to 100%. The activity of all of the human
MMP-13 variants were high in the presence of ER-α. Interestingly, the
activity of the human MMP-13 variants remained unaffected in the
presence of estrogenic ligand, when ER-αwas the modulator (Fig. 5A).
Similar analyses with ER-β are shown in Fig. 5B. The activities
exhibited by the human MMP-13 promoter variants were again
signiﬁcantly increased by the addition of ER-β. Furthermore, all of the
human MMP-13 constructs displayed an ∼80% decrease in their
activity in the presence of 17-β estradiol when ER-β was the
modulator. Thus, some ER isoform-speciﬁc inﬂuences on the MMP-
13 promoter activity may be operative in this system.
4. Discussion
The results of the present study suggest that genetic polymorph-
isms in the promoter of the human MMP-1 and MMP-13 genes can
inﬂuence the response to the modulating inﬂuences of the ER
isoforms. The activities of two well characterized polymorphic
promoter variants of the MMP-1 gene, 1G and 2G were found to
increase with increasing concentrations of ER-α and ER-β. Further-
more, the activity of the 2G variant remained consistently higher than
that of 1G in the absence or presence of ER isoforms. Previous studies
have indicated that the presence of the Ets binding site led to
increased transcription of the 2G variant in both normal ﬁbroblasts
and cancer cells [13,21,23]. Additionally, the proportional increase in
activity for 2G was less than the increase in activity for the 1G variant
at different concentrations of ER-β (see Fig. 1). Moreover, the ratio of
activity of 2G vs. 1G also decreased with increasing concentrations of
ER-β.
When the estrogenic ligand, 17-β estradiol was present at
saturating levels along with ER-β, a suppression of 1G and 2G
promoter activity was observed. Interestingly, repression of 1G
activity when 17-β estradiol was present was insigniﬁcant (pN0.05)
when ER-α was the modulator. In contrast, the activity of the 2G
variant was repressed by the ligand when ER-αwas themodulator but
not to the same extent as was observedwhen ER-βwas themodulator.
These results indicate that ER-β is likely a strongermodulator of MMP-
1 variants than is ER-α. Several independent reports suggest that the
two isoforms of the estrogen receptor have differential inﬂuences on
different MMPs. Previous studies on rabbit MMP-13 regulation have
also demonstrated ER-β to be a stronger modulator of this promoter
than ER-α [11].
Aberrant overexpression of MMP-1 protein has been correlated
with the degradation of stromal layers leading to metastasis of
primary tumor in cancer and also in progression of endometriosis
[22−24]. One study has reported that MMP-1 and ER-β expression are
elevated, but ER-α expression is down-regulated in the endometriotic
lesions, suggesting that estrogenic effects on MMP-1 expression are
modulated primarily through ER-β [25]. Interestingly, bimodal effects
of estrogen have been observed in a study on human retinal pigment
epithelium. A very high level of 17-β estradiol (10−8 M) was found to
suppress ER and MMP-2 expression whereas opposite effects were
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10−10 M [26].
Several studies suggest that the synergistic interaction between
the transcription factors binding to the closely spaced ETS and AP-1
transcription regulatory sites are essential for the basal activation of
the 2G variant of MMP-1 [27,28]. In general, Ets binding proteins have
been shown to bind to both c-fos and c-jun proteins, proteins which
also bind to AP-1 sites [29], and furthermore it has been reported that
Ets-1 and c-jun are the likely candidates to interact and inﬂuence the
MMP-1 promoter activity [14]. The present study also demonstrated
that the Ets and AP-1 sites at locus −1602 and −1607 to be two of the
primary regulatory sites involved in the regulation of the MMP-1
activity in response to ER isoforms. Although, MMP-1 has several
proximal promoter elements, these two distal transcriptional regula-
tory elements appear to play an important role in the stimulation of
MMP-1 promoter activity. In addition, a separate study which focused
on the role of reactive oxygen species on the elevation of MMP-1
promoter activity also established that site-directed mutations of
these Ets and AP-1 sites at nt −1607 and −1602 led to signiﬁcant
decreases in the activity of the MMP-1 promoter [30].
Deletion of the (−1607 bp) Ets and (−1602 bp) AP-1 sites in the
−1458 construct led to a signiﬁcant reduction in the activity of MMP-1
(see Fig. 3), ﬁndings consistent with the results of Nelson et al. [30].
The presence of multiple positive and negative cis-acting transcrip-
tional regulatory elements have been reported in the promoter of the
MMP-1 gene [13]. Moreover the same study also reported the
presence of several putative silencer elements located between
−572 bp and −1772 bp in the MMP-1 promoter. Additionally, a
number of silencer/anti-silencer motifs have been described in the
region between −1653 bp and −2672 bp of the MMP-1 gene and it is
suggested that the anti-silencer motifs override regulation by the
silencer motifs, similar to that seen in the regulation of the vimentin
gene [13,31]. Sequence analysis of the −1458 bp construct used in the
present study revealed the presence of one silencer element and no
anti-silencer elements. This may provide an explanation for the
observed decrease in the transcriptional activity of this construct in
the presence of ER-α and ER-β. It has also been suggested that more
than one silencer element may be required for the repression of the
MMP-1 gene [13], a possibility which may further explain the partial
(∼70%) depression observed in the activity of the −1458 bp construct
compared to the intact 1G construct. Mutation of the PEA-3 site at the
−1385 bp position led to increases in the activity of the −p1485M
construct in the presence of ER-α and ER-β. These results support the
conclusion that the intact PEA-3 site at the −1385 bp position has a
negative regulatory role on the activity of the 1G construct.
Furthermore, as the elevation in activity with −p1458 M was less in
the presence of ER-β than in the presence of ER-α, there may be some
ER isoform-speciﬁc inﬂuences on the impact of this negative
regulatory site.
Interestingly, elevations in the activity of MMP-1 promoter activity
compared to the 1G construct were observed when shorter constructs
(nt −572 and −143) of the promoter were used. The activity of these
two constructs were elevated to somewhat similar levels (p=0.5 when
the activity of the −572 bp construct was compared to the activity of
the −143 bp construct) when ER-αwas themodulator. However, when
ER-β was the modulator, the activity of the −572 bp fragment was
elevated more than that observed for the −143 bp construct. Thus,
these ﬁndings in the present study suggest that ER-α and ER-β may
use different regions of the MMP-1 promoter to mediate their
inﬂuence. Furthermore, based on the studies discussed above, both
of these short constructs lack the putative silencer elements which
might contribute to their higher activity levels in the presence of ER-α
and ER-β. In contrast to the elevated activity levels observed for the
−572 bp promoter construct of MMP-1, the activity of the −73 bp
fragment of the MMP-1 promoter demonstrated decreases in activity
of ∼24% and ∼68% with ER-α or ER-β, respectively. Although the−73 bp construct lacks the putative negative regulatory element, the
present ﬁndings are in agreement with the conclusions of others
[32,33], which indicated that the presence of only the proximal AP-1
element (at −73 bp) is not sufﬁcient to confer maximal transcriptional
activation of the MMP-1 promoter. Previous studies have reported
that phorbol 12-myristate 13-acetate (PMA)-mediated transcriptional
elevation of MMP-1 requires the proximal AP-1 site, as well as the
distal transcriptional regulatory sites [33]. Moreover, studies with the
rabbit collagenase-1(MMP-1) promoter have indicated that mutation
of the AP-1 site at the −77 bp position led to a reduction in the basal
transcription of MMP-1 [34].
Previous studies have indicated that remodeling of connective
tissues occurs in human atherosclerotic lesions and MMPs have been
implicated in this process [35,36,12]. Furthermore, genetic poly-
morphisms in the MMP-13 promoter have been linked to increased
ﬁbrous plaque observed in the abdominal aorta of young black males
[12]. The present study also evaluated the response of MMP-13
polymorphic mutants to the modulatory inﬂuences of the ER-α and
ER-β. The presence of ER-α elevated the activity of MMP-13 promoter
variants (12AA, 12AG, 11AA and 11AG) and addition of the estrogenic
ligand, 17-β estradiol, at saturating concentrations (10−8 M) did not
inﬂuence the MMP-13 activity. However, when ER-β was the
modulator, the human MMP-13 promoter variants did show an
increase in the absence of estrogenic ligand and a decrease in the
presence of 10−8 M 17-β estradiol. Similar to the observations with the
human MMP-13 promoter variants, previous studies have demon-
strated an elevation in the rabbit MMP-13 promoter with both ER-α
and ER-β. In contrast to the human MMP-13 promoter variants, these
elevations in rabbit MMP-13 promoter activity by both ER isoforms is
subject to repression in the presence of 10−8 M estradiol [10,11].
Interestingly, previous studies have reported a higher sequence
homology between the rabbit and human MMP-13 promoter than
between human and mouse MMP-13 promoters [37]. However, the
differences observed in the regulation of the rabbit and human MMP-
13 genes by ER-αmay be attributed in part, to cell-speciﬁc and species
speciﬁc behavior of ER isoforms on the regulation of this gene.
It is well known that binding of steroid hormones to their speciﬁc
intracellular receptors canmodulate gene expressionwithin hormone-
responsive tissues. The results from the present studies suggest that
MMP-1 and MMP-13 promoter variants are inﬂuenced differently by
ER-α and ER-β depending upon the presence or absence of the
hormone estrogen. These ﬁndings may have relevance to the func-
tioning of knee components and bone integrity leading to osteo-
arthritis or osteoporosis in subsets of women following menopause.
Genetic polymorphisms in the MMPs may also contribute to disease
onset and progression in these subsets. Current association studies are
investigating such relationships.
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